

Cortisol ELISA

Enzyme immunoassay for the quantitative determination of Cortisol in human serum and plasma.

> **RE52061** REF

96

፲i 🌋 ∦ 2-8°C

EU: IVD (E

1. INTENDED USE

Enzyme immunoassay for the quantitative determination of cortisol in human serum and plasma.

2. SUMMARY AND EXPLANATION

Cortisol (hydrocortisone, compound F) is the main glucocorticoid in humans and is produced in the zona fasciculata of the adrenal cortex. 90 % of the circulating cortisol are bound to corticoid binding globulin (CBG, Transcortin), ca. 7 % are bound to albumin and only 1–3 % are unbound. Only the latter part represents the active form of cortisol.

In humans there is a physiological fluctuation of cortisol achieving the highest level in the morning and the lowest during midnight. This fluctuation of cortisol plasma level is reflected in saliva normally with a peak in the first 90 minutes after wake up.

The cortisol measurement is indicated in diseases with abnormal glucocorticoid production e.g. Cushing Syndrome and Addison's Disease. Because of the diurnal fluctuation of cortisol levels it is necessary to take several samples for an individual cortisol profile or during dynamic tests like dexamethasone suppression or ACTH stimulation test.

3. TEST PRINCIPLE

Solid phase enzyme-linked immunosorbent assay (ELISA) based on the competition principle. An unknown amount of antigen present in the sample and a fixed amount of enzyme labelled antigen compete for the binding sites of the antibodies coated onto the wells. After incubation the wells are washed to stop the competition reaction. After the substrate reaction the intensity of the developed colour is inversely proportional to the amount of the antigen in the sample. Results of samples can be determined directly using the standard curve.

4. WARNINGS AND PRECAUTIONS

- 1. For *in-vitro diagnostic* use only. For professional use only.
- 2. Before starting the assay, read the instructions completely and carefully. Use the valid version of the package insert provided with the kit. Be sure that everything is understood.
- In case of severe damage of the kit package please contact IBL or your supplier in written form, latest
 one week after receiving the kit. Do not use damaged components in test runs, but keep safe for
 complaint related issues.
- 4. Obey lot number and expiry date. Do not mix reagents of different lots. Do not use expired reagents.
- 5. Follow good laboratory practice and safety guidelines. Wear lab coats, disposable latex gloves and protective glasses where necessary.
- 6. Reagents of this kit containing hazardous material may cause eye and skin irritations. See MATERIALS SUPPLIED and labels for details. Material Safety Data Sheets for this product are available on the IBL-Homepage or upon request directly from IBL.
- 7. Chemicals and prepared or used reagents have to be treated as hazardous waste according to national biohazard and safety guidelines or regulations.
- 8. The cleaning staff should be guided by the professionals regarding potential hazards and handling.
- 9. Avoid contact with Stop solution. It may cause skin irritations and burns.
- 10. All reagents of this kit containing human serum or plasma have been tested and were found negative for anti-HIV I/II, HBsAg and anti-HCV. However, a presence of these or other infectious agents cannot be excluded absolutely. For this reason reagents should be treated as potential biohazards in use and for disposal.

5. STORAGE AND STABILITY

The kit is shipped at ambient temperature and should be stored at 2-8 °C. Keep away from heat or direct sunlight. The storage and stability of specimens and prepared reagents is stated in the corresponding chapters.

The microtiter strips are stable up to the expiry date of the kit in the broken, but tightly closed bag when stored at 2-8 °C.

Version 2014-05 1 / 5

6. SPECIMEN COLLECTION AND STORAGE

Serum, Plasma (EDTA, Heparin, Citrate)

The usual precautions for venipuncture should be observed. It is important to preserve the chemical integrity of a blood specimen from the moment it is collected until it is assayed. Do not use grossly hemolytic, icteric or grossly lipemic specimens. Samples appearing turbid should be centrifuged before testing to remove any particulate material.

| Storage: | 2-8°C | ≤ -20°C (Aliquots) | Keep away from heat or direct sunlight. |
|------------|----------|--------------------|---|
| Stability: | 48 hours | 6 months | Avoid repeated freeze-thaw cycles. |

7. MATERIALS SUPPLIED

| Quantity | Symbol | Component |
|--------------|---------------|--|
| 1 x 12x8 MTP | | Microtiter Plate |
| 1 X 12X0 | | Break apart strips. Coated with anti-cortisol antibodies (rabbit, polyclonal). |
| 1 x 25 mL | ENZCONJ | Enzyme Conjugate |
| 1 X ZO IIIL | ENZOCITO | Ready to use. Contains: Cortisol conjugated to HRP, stabilizers. |
| | | Standard A-G |
| 7 x 1.0 mL | CAL A-G | 0; 20; 50; 100; 200; 400; 800 ng/mL |
| / X 1.0 IIIL | OAL A-O | 0; 55.2; 138; 276; 552; 1104; 2208 nmol/L |
| | | Ready to use. Contains: Cortisol, Human serum, stabilizers. |
| 2 x 1 mL | CONTROL 1 + 2 | Control 1 + 2 |
| ZXIIIL | JOHN NOE 1 12 | Ready to use. Contains: Cortisol, Human serum, stabilizers. |
| 1 x 15 mL | TMB SUBS | TMB Substrate Solution |
| I X I J IIIL | TIME COBC | Ready to use. Contains: TMB, Buffer, stabilizers. |
| 1 x 15 mL | TMB STOP | TMB Stop Solution |
| 1 X 13 IIIL | TMB 0101 | Ready to use. 0.5 M H ₂ SO ₄ . |
| 1 x 100 mL | WASHBUF CONC | Wash Buffer Concentrate (10x) |
| 1 x | FOIL | Adhesive Foil |

8. MATERIALS REQUIRED BUT NOT SUPPLIED

- 1. Micropipettes (Multipette Eppendorf or similar devices, < 3 % CV). Volume: 20; 100; 200 μL
- 2. Vortex mixer
- 3. 8-Channel Micropipettor with reagent reservoirs
- 4. Wash bottle, automated or semi-automated microtiter plate washing system
- 5. Microtiter plate reader capable of reading absorbance at 450 nm (reference wavelength 600-650 nm)
- 6. Bidistilled or deionised water
- 7. Paper towels, pipette tips and timer

9. PROCEDURE NOTES

- 1. Any improper handling of samples or modification of the test procedure may influence the results. The indicated pipetting volumes, incubation times, temperatures and pretreatment steps have to be performed strictly according to the instructions. Use calibrated pipettes and devices only.
- 2. Once the test has been started, all steps should be completed without interruption. Make sure that required reagents, materials and devices are prepared ready at the appropriate time. Allow all reagents and specimens to reach room temperature (18-25 °C) and gently swirl each vial of liquid reagent and sample before use. Mix reagents without foaming.
- 3. Avoid contamination of reagents, pipettes and wells/tubes. Use new disposable plastic pipette tips for each component and specimen. Do not interchange caps. Always cap not used vials. Do not reuse wells/tubes or reagents.
- 4. It is advised to determine samples in duplicate to be able to identify potential pipetting errors.
- 5. Use a pipetting scheme to verify an appropriate plate layout.
- 6. Incubation time affects results. All wells should be handled in the same order and time sequences. It is recommended to use an 8-channel Micropipettor for pipetting of solutions in all wells.

Version 2014-05 2 / 5

- 7. Microtiter plate washing is important. Improperly washed wells will give erroneous results. It is recommended to use a multichannel pipette or an automatic microtiter plate washing system. Do not allow the wells to dry between incubations. Do not scratch coated wells during rinsing and aspiration. Rinse and fill all reagents with care. While rinsing, check that all wells are filled precisely with Wash Buffer, and that there are no residues in the wells.
- 8. Humidity affects the coated wells/tubes. Do not open the pouch until it reaches room temperature. Unused wells/tubes should be returned immediately to the resealed pouch including the desiccant.

10. PRE-TEST SETUP INSTRUCTIONS



The contents of the kit for 96 determinations can be divided into 3 separate runs. The volumes stated below are for one run with all strips (96 determinations).

10.1. Preparation of concentrated components

| ſ | Dilute / dissolve | Component | with | Diluent | Relation | Remarks | Storage | Stability |
|---|----------------------|-----------|--------|---------------|----------|----------------|---------|-----------|
| | 100 mL | WASHBUF | 900 mL | bidist. water | 1:10 | Mix vigorously | 2-8°C | 8 weeks |

10.2. Dilution of Samples

Samples suspected to contain concentrations higher than the highest standard have to be diluted with Standard A. Dilution has to be made in glass tubes. Measured results must be multiplied with the dilution factor to obtain corrected results.

11. TEST PROCEDURE

| 1. | Pipette 20 μL of each Standard, Control and sample into the respective wells of the Microtiter Plate. |
|----|---|
| 2. | Pipette 200 μL of Enzyme Conjugate into each well. |
| 3. | Cover plate with adhesive foil. Thoroughly mix for 10 seconds. |
| 4. | Incubate 60 min at RT (18-25°C). |
| 5. | Remove adhesive foil. Discard incubation solution. Wash plate 3 x with 300 µL of diluted Wash Buffer. |
| | Remove excess solution by tapping the inverted plate on a paper towel. |
| 6. | Pipette 100 μL of TMB Substrate Solution into each well. |
| 7. | Incubate 15 min at RT (18-25°C). |
| 8. | Stop the substrate reaction by adding 100 µL of TMB Stop Solution into each well. |
| | Briefly mix contents by gently shaking the plate. Colour changes from blue to yellow. |
| 9. | Measure optical density with a photometer at 450 nm (Reference-wavelength: 600-650 nm) within 10 min after pipetting of the Stop Solution. |
| | |

12. QUALITY CONTROL

The test results are only valid if the test has been performed following the instructions. Moreover the user must strictly adhere to the rules of GLP (Good Laboratory Practice) or comparable standards/laws. User and/or laboratory must have a validated system to get diagnosis according to GLP. All kit controls must be found within the acceptable ranges as stated on the labels and the QC certificate. If the criteria are not met, the run is not valid and should be repeated. Each laboratory should use known samples as further controls. It is recommended to participate at appropriate quality assessment trials.

In case of any deviation the following technical issues should be proven: Expiration dates of (prepared) reagents, storage conditions, pipettes, devices, incubation conditions and washing methods.

Version 2014-05 3 / 5

13. CALCULATION OF RESULTS

The obtained OD of the standards (y-axis, linear) are plotted against their concentration (x-axis, logarithmic) either on semi-logarithmic graph paper or using an automated method. A good fit is provided with cubic spline, 4 Parameter Logistics or Logit-Log.

For the calculation of the standard curve, apply each signal of the standards (one obvious outlier of duplicates might be omitted and the more plausible single value might be used).

The concentration of the samples can be read directly from the standard curve.

Samples showing concentrations above the highest standard have to be diluted as described in PRE-TEST SETUP INSTRUCTIONS and reassayed.

In case of diluted samples the values have to be multiplied with the corresponding dilution factor.

Conversion:


Cortisol (ng/mL) x 2.76 = nmol/L

Cortisol (μ g/dL) x 27.6 = nmol/L

Typical Calibration Curve

(Example. Do not use for calculation!)

| \ 1 | | , | | |
|----------|-------------------|-------|----------------------|--|
| Standard | Standard Cortisol | | OD/OD _{max} | |
| | (ng/mL) | OD | (%) | |
| Α | 0 | 2.055 | 100 | |
| В | 20 | 1.512 | 73.6 | |
| С | 50 | 1.140 | 55.5 | |
| D | 100 | 0.780 | 37.9 | |
| E | 200 | 0.417 | 20.3 | |
| F | 400 | 0.211 | 10.2 | |
| G | 800 | 0.110 | 5.33 | |



14. EXPECTED VALUES

The results themselves should not be the only reason for any therapeutical consequences. They have to be correlated to other clinical observations and diagnostic tests.

Apparently healthy subjects show the following values:

| | ng/mL | nmol/L |
|----|----------|------------|
| AM | 50 - 230 | 138 - 635 |
| PM | 30 - 150 | 82.8 - 414 |

It is recommended that each laboratory establishes its own range of normal values.

15. LIMITATIONS OF THE PROCEDURE

Specimen collection and storage have a significant effect on the test results. See SPECIMEN COLLECTION AND STORAGE for details.

For cross-reactivities, see PERFORMANCE.

The following blood components do not have a significant effect (+/- 20% of expected) on the test results up to the below stated concentrations:

| | Conc. |
|--------------|-----------|
| Hemoglobin | 8.0 mg/mL |
| Bilirubin | 1.0 mg/mL |
| Triglyceride | 90 mg/mL |

Version 2014-05 4 / 5

16. PERFORMANCE

| | Substance | | Cross Reactivity (%) | | | |
|---|----------------------|----------------------|--|-----------------|--|--|
| | Prednisolone | | 30 | | | |
| | 11-Desoxy-Cortisol | | 7.0 | | | |
| | Corticosterone | | 1.4 Cross-reactivity of their substances | | | |
| Analytical Specificity | Cortisone | | | | | |
| (Cross Reactivity) | Prednisone | | 2.5 | tested < 0.01 % | | |
| | 17α-OH-Progesteron | е | 0.4 | | | |
| | Desoxy-Corticosteror | | 0.9 | | | |
| | 6α-Methyl-17α-OH-P | rogesterone | 0.04 | | | |
| Analytical Sensitivity (Limit of Detection) | 2.46 ng/mL | Mean signal (Zero-St | andard) - 2SD | | | |
| Functional Sensitivity | 4.03 ng/mL | Mean Conc. < 20 % (| CV | | | |
| | | | m ng/mL | | | |
| Precision | Conc. | SD | CV | n | | |
| | (ng/mL) | (ng/mL) | (%) | | | |
| | 43.1 | 1.25 | 2.90 | 20 | | |
| Intra-Assay | 223 | 5.71 | 2.57 | 20 | | |
| | 404 | 14.0 | 3.47 | 20 | | |
| | 68.6 | 3.43 | 5.00 | 20 | | |
| Inter-Assay | 335 | 7.14 | 2.13 | 20 | | |
| | 563 | 19.2 | 3.41 | 20 | | |
| | Dilution | Meas. | Linearity | | | |
| | 4.0 | (ng/mL) | (%) | | | |
| | 1:2 | 51.9 | 98.6 | | | |
| | 1:4 | 29.5 | 113 | | | |
| | 1:8 | 16.8 | 114 | | | |
| | 1:16 | 8.10 | 96.4 | | | |
| Linearity | 1:2 | 321 | 92.7 | | | |
| • | 1:4 | 149 | 97.8 | | | |
| | 1:8 1:16 | 72.8 36.9 | 101 105 | | | |
| | | | | | | |
| | 1:2 | 287 | 101.7 | | | |
| | 1:4 | 131 | 91.1 | | | |
| | 1:8 1:16 | 63.2 32.0 | 96.8 101.3 | | | |
| | | | 101.3 | | | |
| Recovery | Mean (%) | Range (%) 88-106 | - | | | |
| - | 99.9 | 00-100 | | | | |

17. PRODUCT LITERATURE REFERENCES

- Vogelgesang A, May V E L, Grunwald U, Bakkeboe M, Langner S, Wallaschofski H, Kessler CH, Bröker B M, Dressel A. Functional status of peripheral blood T-cells in ischemic stroke patients. PLoS One 2010, 5(1):e8718
- 2 Shamsdin SA, Anvar M, Mehrabani D. The Effect of Exam Stress on Serum IL-6, Cortisol, CRP and IgE Levels. Iranian Red Crescent Medical Journal. 01/01/2010;
- 3 Van de Nieuwegiessen, P. G., 2009. Welfare of African catfish, effects of stocking density. PhD Thesis, Wageningen University, The Netherlands. ISBN: 978-90-8504-986-9
- Bruehl H, Wolf OT, Sweat V, Tirsi A, Richardson S, Convit A. Modifiers of cognitive function and brain structure in middle-aged and elderly individuals with type 2 diabetes mellitus. Brain Res. 2009 Jul 14;1280:186-94. Epub 2009 May 20.
- 5 Andreas Bohringer, Lars Schwabe, Steffen Richter, Hartmut Schachinger. Intranasal insulin attenuates the hypothalamic—pituitary—adrenal axis response to psychosocial stress. Psychoneuroendocrinology (2008) 33, 1394—1400.
- 6 Zubidat AE, Ben-Shlomo R, Haim A. Thermoregulatory and endocrine responses to light pulses in short-day acclimated social voles (Microtus socialis). Chronobiology International, 24(2): 269–288, (2007).
- 7 Sliwa E.Effect of simultaneous versus apart administration of dexamethasone and alpha-ketoglutarate on growth hormone, cortisol and insulin-like growth factor-I in piglets. Bull Vet Inst Pulawy 50, 205-210, 2006

Version 2014-05 5 / 5

Symbols / Symbole / Symbôles / Símbolos / Símbolos / Σύμβολα

| REF | CatNo.: / KatNr.: / No Cat.: / CatNo.: / N.º Cat.: / Ν.–Cat.: / Αριθμός-Κατ.: | | | | |
|----------|--|--|--|--|--|
| LOT | Lot-No.: / Chargen-Bez.: / No. Lot: / Lot-No.: / Lote N.º: / Lotto n.: / Αριθμός -Παραγωγή: | | | | |
| Σ | Use by: / Verwendbar bis: / Utiliser à: / Usado por: / Usar até: / Da utilizzare entro: / Χρησιμοποιείται από: | | | | |
| Σ | No. of Tests: / Kitgröße: / Nb. de Tests: / No. de Determ.: / N.º de Testes: / Quantità dei tests: / Αριθμός εξετάσεων: | | | | |
| CONC | Concentrate / Konzentrat / Concentré / Concentrar / Concentrado / Concentrato / Συμπύκνωμα | | | | |
| LYO | Lyophilized / Lyophilisat / Lyophilisé / Liofilizado / Liofilizado / Liofilizzato / Λυοφιλιασμένο | | | | |
| IVD | In Vitro Diagnostic Medical Device. / In-vitro-Diagnostikum. / Appareil Médical pour Diagnostics In Vitro. / Dispositivo Médico para Diagnóstico In Vitro. / Equipamento Médico de Diagnóstico In Vitro. / Dispositivo Medico Diagnostico In vitro. / Ιατρική συσκευή για In-Vitro Διάγνωση. | | | | |
| ű | Evaluation kit. / Nur für Leistungsbewertungszwecke. / Kit pour évaluation. / Juego de Reactivos para Evaluació. / Kit de avaliação. / Kit di evaluazione. / Κιτ Αξιολόγησης. | | | | |
| []i | Read instructions before use. / Arbeitsanleitung lesen. / Lire la fiche technique avant emploi. / Lea las instrucciones antes de usar. / Ler as instruções antes de usar. / Leggere le istruzioni prima dell'uso. / Διαβάστε τις οδηγίες πριν την χρήση. | | | | |
| 类 | Keep away from heat or direct sun light. / Vor Hitze und direkter Sonneneinstrahlung schützen. / Garder à l'abri de la chaleur et de toute exposition lumineuse. / Manténgase alejado del calor o la luz solar directa. / Manter longe do calor ou luz solar directa. / Non esporre ai raggi solari. / Να φυλάσσεται μακριά από θερμότητα και άμεση επαφή με το φως του ηλίου. | | | | |
| 1 | Store at: / Lagern bei: / Stocker à: / Almacene a: / Armazenar a: / Conservare a: / Αποθήκευση στους: | | | | |
| *** | Manufacturer: / Hersteller: / Fabricant: / Productor: / Fabricante: / Fabbricante: / Παραγωγός: | | | | |
| <u> </u> | Caution! / Vorsicht! / Attention! / ¡Precaución! / Cuidado! / Attenzione! / Προσοχή! | | | | |
| | Symbols of the kit components see MATERIALS SUPPLIED. Die Symbole der Komponenten sind im Kapitel KOMPONENTEN DES KITS beschrieben. | | | | |
| | Voir MATERIEL FOURNI pour les symbôles des composants du kit. | | | | |
| S | ímbolos de los componentes del juego de reactivos, vea MATERIALES SUMINISTRADOS. | | | | |
| | Para símbolos dos componentes do kit ver MATERIAIS FORNECIDOS. | | | | |
| | Per i simboli dei componenti del kit si veda COMPONENTI DEL KIT. | | | | |

COMPLAINTS: Complaints may be submitted initially written or vocal. Subsequently they need to be filed including the test performance and results in writing in case of analytical reasons.

Για τα σύμβολα των συστατικών του κιτ συμβουλευτείτε το ΠΑΡΕΧΟΜΕΝΑ ΥΛΙΚΑ.

WARRANTY: The product is warranted to be free from material defects within the specific shelf life and to comply with product specifications delivered with the product. The product must be used according to the Intended use, all instructions given in the instructions for use and within the product specific shelf life. Any modification of the test procedure or exchange or mixing of components of different lots could negatively affect the results. These cases invalidate any claim for replacement.

LIMITATION OF LIABILITY: IN ALL CIRCUMSTANCES THE EXTENT OF MANUFACTURER'S LIABILITY IS LIMITED TO THE PURCHASE PRICE OF THE KIT(S) IN QUESTION. IN NO EVENT SHALL MANUFACTURER BE LIABLE FOR ANY INCIDENTAL OR CONSEQUENTIAL DAMAGES, INCLUDING DAMAGES FOR LOST PROFITS, LOST SALES, INJURY TO PERSON OR PROPERTY OR ANY OTHER INCIDENTAL OR CONSEQUENTIAL LOSS.

| IBL International GmbH Flughafenstr. 52A, 22335 Hamburg, Germany | Tel.: E-MAIL: WEB: | + 49 (0) 40 532891 -0 Fax: -11 IBL@IBL-International.com http://www.IBL-International.com |
|--|--------------------------|---|
|--|--------------------------|---|